Wednesday, November 11, 2026
Barclays kept its Overweight rating on Xeris Biopharma (XERS) and raised its price target to $18 from $14.
Friday, November 6, 2026
Oppenheimer kept its Outperform rating on Xeris Biopharma (XERS) with a price target of $21.
Piper Sandler kept its Neutral rating on Xeris Biopharma (XERS) with a price target of $12.
HC Wainwright & Co. kept its Buy rating on Xeris Biopharma (XERS) with a price target of $18.
Tuesday, October 6, 2026
Barclays kept its Overweight rating on Xeris Biopharma (XERS) and raised its price target to $14 from $12.
Thursday, September 10, 2026
Leerink Partners kept its Outperform rating on Xeris Biopharma (XERS) with a price target of $16.
Thursday, August 20, 2026
Barclays kept its Overweight rating on Xeris Biopharma (XERS) with a price target of $12.
Frequently asked questions
What is the latest news on XERS?
Nov 11, 2026: Barclays kept its Overweight rating on Xeris Biopharma (XERS) and raised its price target to $18 from $14. (Barclays) · Nov 6, 2026: Oppenheimer kept its Outperform rating on Xeris Biopharma (XERS) with a price target of $21. (Oppenheimer) · Nov 6, 2026: Piper Sandler kept its Neutral rating on Xeris Biopharma (XERS) with a price target of $12. (Piper Sandler)
What are analysts saying about XERS?
Nov 11, 2026: Barclays kept its Overweight rating on Xeris Biopharma (XERS) and raised its price target to $18 from $14. · Nov 6, 2026: Oppenheimer kept its Outperform rating on Xeris Biopharma (XERS) with a price target of $21. · Nov 6, 2026: Piper Sandler kept its Neutral rating on Xeris Biopharma (XERS) with a price target of $12.
Get XERS news as it happens
Every headline, SEC filing and analyst action for XERS on your live chart, with important news marked and alerts when it matters.
Try SEPT Free